Newbridge Financial Services Group’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.73K | Buy |
+200
| New | +$9.73K | ﹤0.01% | 897 |
|
|
2025
Q1 | – | Sell |
-29
| Closed | -$1.14K | – | 1064 |
|
|
2024
Q4 | $1.14K | Sell |
29
-171
| -86% | -$6.73K | ﹤0.01% | 1009 |
|
|
2024
Q3 | $9.4K | Sell |
200
-576
| -74% | -$27.1K | ﹤0.01% | 437 |
|
|
2024
Q2 | $41.9K | Hold |
776
| – | – | 0.02% | 408 |
|
|
2024
Q1 | $52.9K | Sell |
776
-300
| -28% | -$20.4K | 0.02% | 386 |
|
|
2023
Q4 | $67.4K | Buy |
1,076
+358
| +50% | +$22.4K | 0.03% | 339 |
|
|
2023
Q3 | $32.6K | Buy |
718
+200
| +39% | +$9.08K | 0.02% | 529 |
|
|
2023
Q2 | $29.1K | Hold |
518
| – | – | 0.01% | 590 |
|
|
2023
Q1 | $23.4K | Hold |
518
| – | – | 0.01% | 663 |
|
|
2022
Q4 | $21.1K | Hold |
518
| – | – | 0.01% | 705 |
|
|
2022
Q3 | $34K | Buy |
518
+2
| +0.4% | +$131 | 0.02% | 552 |
|
|
2022
Q2 | $31K | Sell |
516
-337
| -40% | -$20.2K | 0.02% | 519 |
|
|
2022
Q1 | $54K | Buy |
853
+288
| +51% | +$18.2K | 0.03% | 461 |
|
|
2021
Q4 | $43K | Buy |
565
+279
| +98% | +$21.2K | 0.02% | 506 |
|
|
2021
Q3 | $32K | Buy |
286
+51
| +22% | +$5.71K | 0.02% | 538 |
|
|
2021
Q2 | $38K | Hold |
235
| – | – | 0.02% | 528 |
|
|
2021
Q1 | $29K | Sell |
235
-1,150
| -83% | -$142K | 0.02% | 589 |
|
|
2020
Q4 | $212K | Sell |
1,385
-259
| -16% | -$39.6K | 0.17% | 131 |
|
|
2020
Q3 | $138K | Buy |
+1,644
| New | +$138K | 0.14% | 155 |
|